Biosimilar Remicade under review in EU

April 13, 2012 8:08 AM

EMA, European Medicines Agency’s latest list of validated new drug applications shows us that, there’s a biosimilar application for infliximab, the generic name of Merck & Co and Johnson&Johnson’s Remicade.

The European watchdog did not identify the company but according to Reuters, the company is most probably, Celltrion.

Celltrion is a South Korean company and has already declared the positive results of their biosimilar infliximab study. Celltrion has several monoclonal antibody biosimilars in their portfolio and Herceptin, Roche&Genentech’s breast and gastric cancer blockbuster is also their point of interest.

Remicade biosimilar will be the first monoclonal antibody in the European market. Up to now, Europe has approved biosimilar versions of human growth hormones, G-CSFs and Epoetins but no monoclonal antibody biosimilar was registered by EMA yet.

You can check the list of applications which are under review by CHMP from here.

 

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!